Sriram Ryali - 10 May 2021 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
Chief Financial Officer
Signature
/s/ Sriram Ryali
Issuer symbol
N/A
Transactions as of
10 May 2021
Net transactions value
$0
Form type
4
Filing time
11 May 2021, 20:32:30 UTC
Next filing
30 Jul 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +87,000 $0.000000 87,000 10 May 2021 Common Stock 87,000 $8.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in equal monthly installments over 48 months measured from May 10, 2021 subject to Reporting Person's continuous service status as of each such date.